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Background: The TRIM5α restriction factor interferes with retroviral infections by inhibiting an early step of viral
replication. TRIM5α activity was recently proposed to be regulated by the SUMO machinery and one SUMO
consensus conjugation site as well as three putative SUMO interacting motifs (SIMs) were identified within TRIM5α
sequence. Whereas mutation of the SIM sequences was found to abolish TRIM5α antiviral activity, mutation of the
consensus SUMO conjugation site did not affect its restriction capacity, although this putative site has never been
shown to be actually a SUMO substrate.
Findings: Here we further demonstrate that TRIM5α relies on the SUMO machinery to promote restriction,
since SUMO1 overexpression enhances TRIM5α-mediated retroviral inhibition whereas knockdown of SUMO1 or
E2 SUMO conjugating enzyme Ubc9 prevents restriction. Furthermore, we show for the first time that TRIM5α
is SUMOylated both in vitro and in cellulo and that Lysine 10 is the main SUMOylation site. Mutation of the
consensus SUMO conjugation motif in position 10 abrogated SUMOylation at this position, but did not disrupt
TRIM5α antiviral activity.
Conclusions: Altogether, our results confirm that the SUMO machinery is involved in TRIM5α-mediated retroviral
restriction, and demonstrate that TRIM5α is a SUMO 1 and SUMO 2 substrate. The inability to abrogate TRIM5α
antiviral activity by mutating its main SUMO conjugation motif supports the notion that non-covalent interaction
with SUMO or SUMOylated proteins rather than TRIM5α direct SUMOylation is required.
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TRIM5α is a restriction factor that interferes with an early
step of retroviral replication in a species-dependent man-
ner. Rhesus macaque TRIM5α (rhTRIM5α) is a potent in-
hibitor of HIV-1 infection, whereas its human counterpart
(hTRIM5α) only weakly restricts HIV-1 [1,2]. TRIM5α is a
cytoplasmic protein belonging to the TRIpartite Motif
protein family (TRIM), a family of proteins characterized
by their conserved structure composed, from N to C-
terminus, by a RING domain, one or two B-Boxes and a
Coiled-coil domain [3]. TRIM proteins mainly differ from
each other by the nature of their C-terminal domain(s),
which is a B30.2/SPRY domain in the case of TRIM5α.
This domain allows TRIM5α to bind the viral capsid
lattice of incoming particles and is therefore responsible
for its species-specific activities.* Correspondence: sebastien.nisole@inserm.fr
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unless otherwise stated.Most TRIM proteins, including TRIM5α, self-associate
into corpuscules, either cytoplasmic or nuclear [4]. One of
the best-characterized members of this protein family is
TRIM19, better known as promyelocytic leukemia protein
(PML). TRIM19/PML is expressed in the nucleus, both in
the nucleoplasm and in discrete subnuclear compartments
known as PML nuclear bodies (reviewed in [5]). Modifica-
tion of TRIM19/PML by small ubiquitin-related modifier
(SUMO) has been demonstrated to modulate its stability,
sub-nuclear localization and functions [5,6].
SUMOs are small ubiquitin-like proteins that are post-
translationally conjugated to other proteins, thereby
regulating a wide range of biological processes, including
transcription, DNA repair, chromosome dynamics and
subcellular localization of target proteins (reviewed in
[7,8]). The SUMO family consists of four members,
termed SUMO1 to 4. SUMO is conjugated to protein
substrates via an ATP-dependent enzymatic pathway
involving 4 enzymes, a SUMO protease, an E1-activating
enzyme, an E2-conjugating enzyme (Ubc9) and an E3
ligase, via a mechanism essentially analogous to that ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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also interact non-covalently with SUMO or SUMO-
conjugated proteins via a SUMO-interacting motif (SIM)
[7]. Three SIMs have been identified within TRIM5α
B30.2 domain. Interestingly, mutation of two of these
SIMs was shown to abolish TRIM5α-mediated restriction
[9,10]. It is still unknown, however, whether TRIM5α is
covalently modified by SUMO and whether SUMO con-
jugation could affect its activity.
We first evaluated the implication of SUMO machinery
in TRIM5α-mediated antiviral activity. For this purpose,Figure 1 SUMOylation regulates rhTRIM5α-mediated HIV-1 restriction.
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down of endogenous SUMO1, Ubc9 (the E2 SUMO
conjugating enzyme) or PIAS1 (an E3 SUMO ligase)
expression on rhTRIM5α anti-HIV activity. As shown
in Figure 1A, transfection of HeLa cells with control
siRNA or with siRNA targeting SUMO1, Ubc9 or
PIAS1 did not have any effect on HIV-1 infection. In
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rhTRIM5α (Figure 1A). Silencing of PIAS1 partially re-
versed rhTRIM5α-mediated HIV-1 restriction, suggesting
that this E3-SUMO ligase is also likely to be implicated
in TRIM5α restriction.
In order to confirm these results, we tested whether
SUMO1 was capable of modulating rhTRIM5α-mediated
HIV-1 restriction by transfecting SUMO1 in HeLa cells
expressing or not rhTRIM5α. The expression level of
rhTRIMα was reduced compared to panel 1A, in order
to limit the amplitude of HIV-1 restriction. As shown in
Figure 1B, overexpression of SUMO1 did not have any
effect on HIV-1 infection of HeLa cells. In contrast, in
rhTRIMα expressing cells, expression of SUMO1 led to
a further decrease in HIV-1 infection. This observation
clearly demonstrates that SUMO1 overexpression en-
hances the anti-HIV activity of rhTRIM5α. Altogether,
these observations indicate that the SUMO machinery
regulates rhTRIM5α-mediated restriction of HIV-1. This
could indicate either that TRIM5α SUMOylation is
required for HIV-1 restriction or that TRIM5α needs
other proteins to be SUMOylated to display its antiviral
activity.Figure 2 Human and rhesus macaque TRIM5α are SUMO substrates. A
incubated with purified recombinant E1 (SAE1 and SAE2 subunits, 370 nM)
and increasing doses of GST-PIAS1 (0, 0.3 or 1.5 μM) or GST alone (0.3 or 1.
B. HeLa cells expressing HA-tagged hTRIM5α or rhTRIM5α were transfected w
analyzed by SDS-PAGE and immunoblotted with anti-HA antibodies. Al
affinity chromatography (IMAC) on nickel-agarose beads under strongly
analyzed by SDS-PAGE and immunoblotted with anti-HA antibodies. Th
whereas black arrows indicate the position of SUMOylated forms.To confirm interaction of TRIM5α with SUMO or
SUMOylated proteins, we performed Duolink in situ prox-
imity ligation assay (PLA). Cells were probed with anti-
TRIM5α and anti-SUMO1 primary antibodies, followed
by species-specific PLA probes. Our results show close
proximity of TRIM5α with SUMO1, with an average of
38.6 spots per cell +/- 8.9 (SD), compared with 0.41 spots
per cell +/- 0.39 for the PLA probes alone control. These
results confirm that endogenous TRIM5α is conjugated by
SUMO or interacts with SUMOylated proteins. Similar
results were obtained following infection with HIV-1 (data
not shown).
In order to determine whether TRIM5α itself can be
a substrate for SUMO modification, we employed an
in vitro SUMOylation assay using purified recombinant
E1 (SAE1 and SAE2 subunits) and E2 (Ubc9) enzymes,
recombinant SUMO1 or SUMO2, and increasing doses
of GST-tagged PIAS1 E3-ligase or GST alone, as control.
As a substrate, we used in vitro translated 35S-labelled hu-
man or rhesus macaque TRIM5α. As shown in Figure 2A,
in the absence of SUMO, a single band of 55 kDa corre-
sponding to the unmodified TRIM5α can be observed.
When SUMO1 or SUMO2 was added to the reaction, an. In vitro translated human or rhesus macaque TRIM5α proteins were
, E2 (Ubc9, 630 nM) enzymes, recombinant SUMO1 or SUMO2 (7 μM),
5 μM) as control. Reaction products were analyzed by 10% SDS-PAGE.
ith Ubc9 and 6xHis-SUMO1, when indicated (+). Cell lysates were directly
ternatively, cell extracts were subjected to an immobilized-metal
denaturing conditions and 6xHis-SUMO conjugated proteins were
e position of unmodified TRIM5α is indicated by an asterisk
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and corresponds to the expected size for TRIM5α conju-
gated to one SUMO1 moiety, thus demonstrating that
both human and rhesus macaque TRIM5α proteins can
be SUMOylated in vitro. Interestingly, we observed an
enhancement of SUMO1 and SUMO2 conjugation to
both human and rhesus macaque TRIM5α when the reac-
tion was performed with increasing concentrations of
GST-PIAS1.
Next, we sought to verify whether TRIM5α could also
be SUMOylated in cellulo. Since no high molecular weight
form of TRIM5α could be detected in wt HeLa cells (not
shown), we co-transfected human or rhesus macaque
HA-tagged TRIM5α with Ubc9 in order to boost theFigure 3 TRIM5α is SUMO-modified on lysine 10. A. Schematic represen
predicted SUMOylated sites, S1 and S2. B. Wild-type hTRIM5α, rhTRIM5α, or
and used as a substrate for in vitro SUMO-conjugation assay as described in
were transfected with empty vector (ev), wt or S1m rhTRIM5α and transdu
48 hours, the proportion of GFP-positive cells was measured by flow cytom
three independent experiments.SUMOylation machinery. Two days post-transfection, cell
extracts were analyzed by western-blot, revealing two
bands, a major band at 55 kDa, which corresponds to
unmodified TRIM5α, and a faint band at approximately
75 kDa, which corresponds to the expected size for
TRIM5α conjugated to one SUMO moiety (Figure 2B).
Interestingly, transfection of 6xHis-SUMO1 globally en-
hanced the proportion of high molecular weight bands,
clearly revealing the existence of 3 species at approxi-
mately 75, 95 and 115 kDa (Figure 2B). These three slow-
migrating bands of decreasing intensity may correspond
to TRIM5α conjugated to one, two or three SUMO1
moieties, respectively. Alternatively, the higher molecular
weight bands may represent mono-SUMOylated TRIM5αtation of human and rhesus macaque TRIM5α proteins, indicating the
the mutants S1m, S2m and S1S2m were in vitro translated, 35S-labelled
Figure 2. Reaction products were analyzed by SDS-PAGE. C. HeLa cells
ced two days later with increasing concentrations of HIV-1/GFP. After
etry. Graphs shows means of triplicate values +/- SD, representative of
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ubiquination, ISGylation, or neddylation. In order to
verify whether these bands correspond to SUMOylated
forms of TRIM5α, cell lysates were prepared under
strongly denaturing conditions and proteins conjugated
to 6xHis-SUMO1 were purified by immobilized-metal
affinity chromatography (IMAC). Bound proteins were
separated by SDS-PAGE and the presence of TRIM5α-
HA was detected by western-blot (Figure 2B). As
expected, three distinct bands can be detected at 75,
95 and 115 kDa, thus confirming the existence of 3
distinct SUMOylated forms of TRIM5α in SUMO1
overexpressing cells.
For most target proteins, SUMOylation occurs on a
conserved consensus motif ΨKXE (where Ψ is a hydro-
phobic amino acid) [7,8]. TRIM5α sequences contain two
predicted SUMOylation sites, VK10EE (S1) and LK263KP
(S2) in hTRIM5α, and VK10EE (S1) and LK265KP (S2) in
rhTRIM5α. The first potential SUMO-conjugation site,
referred to as S1, is located at the N-terminal extremity of
the protein, before the RING domain, whereas the second
putative site, S2, is located between the coiled-coil and the
B30.2 domain (Figure 3A).
To determine whether either of these lysines are ac-
ceptor sites for SUMO1 conjugation, two single K to R
point mutants were generated in human and rhesus
macaque TRIM5α at K10 (S1m) and K263 or K265
(S2m), as well as double mutants (S1S2m). These con-
structs were tested in the in vitro SUMOylation assay.
As shown in Figure 3B, the 75 kDa band can still be
detected with S2m but not with S1m or with the double
mutant, thus demonstrating that K10 is the major
SUMOylation site within TRIM5α from both species.
Identical results were obtained when the SUMOylation
reactions were performed in the presence of SUMO2
instead of SUMO1 (Figure 3B).
Finally, we looked at the phenotype of S1 mutants
by testing their capacity to restrict retroviral infec-
tions. Despite dramatic SUMOylation defects in vitro,
rhTRIM5α S1m showed the same anti-HIV-1 activity
than the wild-type protein, thus demonstrating that
TRIM5α SUMOylation is not required for retroviral
restriction, at least in HeLa cells (Figure 3C).
Although TRIM5α was suspected to be SUMOylated
and that K10 was identified as a SUMOylation consen-
sus site [9-11], TRIM5α SUMOylation has never been
observed, neither in cellulo nor in vitro. This report is
the first to demonstrate that TRIM5α is a SUMO sub-
strate and to experimentally confirm that K10 is the
main SUMOylation site. Previous groups have attempted
to detect TRIM5α SUMOylation but without success
[9-11]. Indeed the demonstration of TRIM5α SUMOy-
lation by in vitro nickel pulldown assay required
optimization of SUMO and Ubc9 expression and ofbinding conditions, which together may point to the
fact that SUMOylation is transitory and affects only a
small proportion of a given protein. Since rhTRIM5α
K10R mutant is still able to restrict HIV-1, our
results support the fact that the capacity of TRIM5α
to interact with SUMOylated proteins, via its SIMs,
rather than its direct SUMOylation, is required for its
antiretroviral activity [9,10]. However, what is true for
transfected TRIM5α is not necessarily applicable to
the endogenous protein, particularly since endogenous
TRIM5α is present in very small quantities. Indeed, it
is possible that TRIM5α SUMOylation is important in
certain cell types, to control TRIM5α activity and/or
sub-cellular localization. We previously reported that
dendritic cells from rhesus macaques are unable to
restrict HIV-1, even if they express TRIM5α [12]. We are
now conducting experiments to investigate whether this
lack of restriction could be due to TRIM5α SUMOylation
status.
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